Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma Inc. received an updated Schedule 13G/A from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership in the company’s common stock. As of June 30, 2026, they may be deemed to beneficially own 235,697 shares of common stock issuable upon exercise of a warrant, representing 9.99% of the outstanding common stock. This percentage is calculated using 2,123,635 shares outstanding as of May 28, 2026 plus the 235,697 warrant shares. Additional warrant shares are contractually blocked from exercise above ownership caps of 9.99% for one warrant and 4.99% for another, which limits the reportable beneficial ownership.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sunshine Biopharma Inc. director Natan David received a stock award of 58,300 shares of common stock on August 7, 2026. The award was granted at a stated price of $0.00 per share and increased his directly held position to 68,300 common shares following the transaction. A footnote clarifies that this represents a stock award to the reporting person.
Sunshine Biopharma Inc. reports that, as a result of recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This exercise price remains subject to further adjustment under the terms of the Series B Warrants.
Sunshine Biopharma Inc. is initiating an at-the-market common stock offering of up to $4,000,000 under a Sales Agreement with Aegis Capital Corp., acting as exclusive sales agent. Shares may be sold from time to time on Nasdaq as defined in Rule 415.
The company will pay Aegis a 3.0% cash commission on gross proceeds and reimburse specified expenses, and Aegis will be deemed an underwriter. Net proceeds are intended for general corporate purposes, including working capital. Under General Instruction I.B.6 of Form S-3, primary offerings are limited to one-third of non-affiliate market value while it remains below $75 million.
Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp., allowing the company to sell shares of its common stock from time to time for an aggregate offering price of up to $4,000,000 in at-the-market offerings through or to Aegis as exclusive sales agent.
Sales may be effected directly on or through the Nasdaq Capital Market or other existing trading markets under Rule 415(a)(4). Aegis will receive a 3.0% commission on gross proceeds plus certain reimbursed expenses. Neither party is obligated to transact, and both may terminate the agreement. The shares will be issued under the company’s shelf registration statement on Form S-3 (File No. 333-284142), effective January 15, 2025, and a July 20, 2026 prospectus supplement.
Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.
Sunshine Biopharma Inc. ownership disclosure: Alta Partners LLC reports beneficial ownership of 200,000 shares of common stock, representing 8.6% of the class as of 07/08/2026. The filing states these shares are issuable upon exercise of outstanding warrants and lists Sole Voting and Sole Dispositive Power of 200,000 shares.
Sunshine Biopharma Inc. delivered an information statement reporting that holders of a majority of voting power approved by written consent certain Warrant Stockholder Approval Provisions for the Series C Warrants issued in a May 19, 2026 public offering. The approval was obtained from Dr. Steve N. Slilaty, who held 86.0% of voting power as of May 28, 2026.
The Offering issued 1,116,000 Common Units and 84,000 Pre-Funded Units (aggregate gross proceeds of approximately $6.0 million) and included Series C Warrants exercisable at an initial price of $5.00 per share. The information statement notes a 10-for-1 reverse split effective June 1, 2026 and states the Warrant Stockholder Approval will become effective 20 days after mailing this statement.
Sunshine Biopharma Inc. used written stockholder consent to approve the Warrant Stockholder Approval Provisions, effective 20 days after mailing the definitive information statement. The approval follows a May 19, 2026 offering that issued 11,160,000 Common Units and 840,000 Pre-Funded Units, raising aggregate gross proceeds of approximately $6 million before fees and expenses. The Series C Warrants issued in the offering carry a $0.50 initial exercise price, five-year term, and exercise ownership limits of 4.99% (or, if elected, 9.99%). The company estimates mailing costs of approximately $25,000.
Sunshine Biopharma Inc. reports that its majority stockholder, CEO Dr. Steve N. Slilaty, approved by written consent several actions tied to the company’s recent public offering that closed on May 19, 2026. The approval covers issuing more than twenty percent of the outstanding common shares at a deemed discount to the Nasdaq Minimum Price and allows certain exercise price and share-count adjustments for Series C Warrants in connection with a Share Combination Event or voluntary exercise price changes. The consent becomes effective 20 days after a definitive information statement is mailed to stockholders, with Dr. Slilaty holding approximately 86% of the total voting power.